A Review on SARS-CoV-2 Virology, Pathophysiology, Animal Models, and Anti-Viral Interventions

被引:41
|
作者
Neerukonda, Sabari Nath [1 ]
Katneni, Upendra [1 ,2 ]
机构
[1] Univ Delaware, Dept Anim & Food Sci, Newark, DE 19716 USA
[2] Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA
来源
PATHOGENS | 2020年 / 9卷 / 06期
关键词
SARS-CoV-2; COVID-19; animal models; antivirals; RESPIRATORY SYNDROME CORONAVIRUS; BROAD-SPECTRUM; CONVALESCENT PLASMA; ROTAVIRUS DIARRHEA; POTENT INHIBITORS; DOUBLE-BLIND; NITAZOXANIDE; SARS; VIRUS; MERS;
D O I
10.3390/pathogens9060426
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of CoV disease 2019 (COVID-19) is a highly pathogenic and transmissible CoV that is presently plaguing the global human population and economy. No proven effective antiviral therapy or vaccine currently exists, and supportive care remains to be the cornerstone treatment. Through previous lessons learned from SARS-CoV-1 and MERS-CoV studies, scientific groups worldwide have rapidly expanded the knowledge pertaining to SARS-CoV-2 virology that includes in vitro and in vivo models for testing of antiviral therapies and randomized clinical trials. In the present narrative, we review SARS-CoV-2 virology, clinical features, pathophysiology, and animal models with a specific focus on the antiviral and adjunctive therapies currently being tested or that require testing in animal models and randomized clinical trials.
引用
收藏
页数:22
相关论文
共 50 条
  • [31] Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)
    Li Runfeng
    Hou Yunlong
    Huang Jicheng
    Pan Weiqi
    Ma Qinhai
    Shi Yongxia
    Li Chufang
    Zhao Jin
    Jia Zhenhua
    Jiang Haiming
    Zheng Kui
    Huang Shuxiang
    Dai Jun
    Li Xiaobo
    Hou Xiaotao
    Wang Lin
    Zhong Nanshan
    Yang Zifeng
    [J]. PHARMACOLOGICAL RESEARCH, 2020, 156
  • [32] Gramicidin S and melittin: potential anti-viral therapeutic peptides to treat SARS-CoV-2 infection
    Mohammed Ghalib Enayathullah
    Yash Parekh
    Sarena Banu
    Sushma Ram
    Ramakrishnan Nagaraj
    Bokara Kiran Kumar
    Mohammed M. Idris
    [J]. Scientific Reports, 12
  • [33] Virology, transmission, and pathogenesis of SARS-CoV-2
    Cevik, Muge
    Kuppalli, Krutika
    Kindrachuk, Jason
    Peiris, Malik
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2020, 371
  • [34] Cell and Animal Models for SARS-CoV-2 Research
    Bestion, Eloine
    Halfon, Philippe
    Mezouar, Soraya
    Mege, Jean-Louis
    [J]. VIRUSES-BASEL, 2022, 14 (07):
  • [35] Keynote Lecture "Anti-viral Drug Discovery for Severe Acute Respiratory Syndrome (SARS-CoV-2)"
    Quinn, R.
    Liu, M.
    Gu, Y.
    Mak, T.
    Belden, E.
    [J]. PLANTA MEDICA, 2022, 88 (15) : 1403 - 1403
  • [36] Animal models for SARS-CoV-2 infection and pathology
    Bi, Zhenfei
    Hong, Weiqi
    Yang, Jingyun
    Lu, Shuaiyao
    Peng, Xiaozhong
    [J]. MEDCOMM, 2021, 2 (04): : 548 - 568
  • [37] Targeting cytokine storm as the potential anti-viral therapy: Implications in regulating SARS-CoV-2 pathogenicity
    Maity, Subhasish
    Santra, Ayantika
    Hebbani, Ananda Vardhan
    Pulakuntla, Swetha
    Chatterjee, Ankita
    Badri, Kameswara Rao
    Reddy, Vaddi Damodara
    [J]. GENE, 2023, 881
  • [38] Gramicidin S and melittin: potential anti-viral therapeutic peptides to treat SARS-CoV-2 infection
    Enayathullah, Mohammed Ghalib
    Parekh, Yash
    Banu, Sarena
    Ram, Sushma
    Nagaraj, Ramakrishnan
    Kumar, Bokara Kiran
    Idris, Mohammed M.
    [J]. SCIENTIFIC REPORTS, 2022, 12 (01)
  • [39] In Vitro and Animal Models for SARS-CoV-2 research
    Takayama, Kazuo
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2020, 41 (08) : 513 - 517
  • [40] The Mechanisms and Animal Models of SARS-CoV-2 Infection
    Jia, Wenrui
    Wang, Juan
    Sun, Bao
    Zhou, Jiecan
    Shi, Yamin
    Zhou, Zheng
    [J]. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9